Completed PHASE1 INTERVENTIONAL NCT00003755

Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor

Phase I Study of R031-7453, a Novell Cell Cycle Inhibitor, Administered as Escalating Oral Doses in Adults With Solid Tumors: 4-Day Schedule

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Unspecified Adult Solid Tumor, Protocol Specific

Interventions MKC-1

Updated 5 times since 2017 Last updated: Jun 24, 2013 Started: Oct 31, 1998 Primary completion: Aug 31, 2001 Completion: Aug 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003755, this PHASE1 trial focuses on Unspecified Adult Solid Tumor, Protocol Specific and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States